JO
VIRX

John Overdeck’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

John Overdeck’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-14,549
Closed -$23.1K – 3338
2023
Q1 		$23.1K Sell
14,549
-45,225
-76% -$82.2K ﹤0.01% 2840
2022
Q4 		$87.3K Buy
+59,774
New +$175K ﹤0.01% 2524
2022
Q1 		– Sell
-159,331
Closed -$582K – 4585
2021
Q4 		$582K Buy
+159,331
New +$850K ﹤0.01% 3101
2020
Q1 		– Sell
-12,790
Closed -$151K – 3950
2019
Q4 		$151K Buy
12,790
+10,143
+383% +$170K ﹤0.01% 3474
2019
Q3 		$67K Sell
2,647
-1,755
-40% -$50.6K ﹤0.01% 3340
2019
Q2 		$112K Buy
+4,402
New +$170K ﹤0.01% 3189
2019
Q1 		– Sell
-1,032
Closed -$15K – 3544
2018
Q4 		$15K Sell
1,032
-1,034
-50% -$42.2K ﹤0.01% 2894
2018
Q3 		$145K Sell
2,066
-934
-31% -$70.9K ﹤0.01% 3052
2018
Q2 		$223K Buy
3,000
+2,445
+441% +$218K ﹤0.01% 3091
2018
Q1 		$53K Buy
+555
New +$95.2K ﹤0.01% 3064
2015
Q1 		– Sell
-85
Closed -$46K – 2908
2014
Q4 		$46K Sell
85
-757
-90% -$341K ﹤0.01% 2166
2014
Q3 		$1.26M Buy
842
+787
+1,431% +$1.14M 0.01% 1002
2014
Q2 		$76K Buy
+55
New +$63.8K ﹤0.01% 2067
2014
Q1 		– Sell
-91
Closed -$90K – 2313
2013
Q4 		$90K Buy
+91
New +$94.1K ﹤0.01% 2090

Other funds holding VIRX

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $26.6B AUM 22.97% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

John Overdeck's VIRX Position: Q2 2023 in Review

John Overdeck sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q2 2023, closing a stake of 14,549 shares — an estimated $23.1K sold.

John Overdeck first reported a position in VIRX in Q4 2013 and held it in 14 quarters. The position peaked at $1.26M in Q3 2014. 41 funds tracked by Wall St. Rank hold VIRX as of Q2 2023.

  • John Overdeck reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • John Overdeck sold 14,549 Viracta Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $23.1K.
  • John Overdeck first reported a position in Viracta Therapeutics, Inc. Common Stock in Q4 2013 and held it in 14 quarters.
  • John Overdeck's Viracta Therapeutics, Inc. Common Stock position peaked at $1.26M in Q3 2014.
  • 41 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Two Sigma Investments's 13F filing for Q2 2023, filed 14 Aug 2023.